Registered title, quoted from ClinicalTrials.gov
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Pulmonary Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06987734, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically documented, stage II-IIIA Non-Small Cell Lung Cancer (according to version 9th of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and previously untreated.
Inclusion criterion 3
Histologically confirmed adenosquamous carcinoma 7) Any prior treatment of antibody/drug that targets at T-cell coregulatory proteins 8) Subjects have interstitial lung disease (ILD), or a history of ILD that required corticosteroid treatment.
Exclusion criterion 4
ECOG Performance Status of 0 or 1
Inclusion criterion 5
Hemoglobin(HB)≥90g/L;
Inclusion criterion 9
Absolute neutrophils count(ANC)≥1.5×109/L;
Inclusion criterion 10
Blood platelets(PLT)≥100×109/L
Inclusion criterion 11
Total bilirubin(TBIL)≤1.5 times the upper limit of normal (ULN) ;
Inclusion criterion 12
Alanine aminotransferase (ALT) and aspartate aminotransgerase AST≤2.5*ULN,
Inclusion criterion 13
Creatinine(Cr)≤1.5*ULN or Creatinine Clearance rate (CCr)≥60 ml/min; Coagulation test: INR/APTT within normal limits Doppler ultrasound assessment:left ventricular ejection fraction (LVEF) ≥the lower limit of normal value (50%).
Inclusion criterion 14
1) All patients carrying activating mutations in the TK domain of EGFR or any variety of alterations in the ALK gene.
Exclusion criterion 1
At least 1 unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
Inclusion criterion 6
Women in pregnancy or lactation. 10) Patients who are allergic to any of the agent or any ingredient
Exclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06987734, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥ 18 years
- Patients have voluntarily to join the study and give written informed consent for the study.
- Histologically documented, stage II-IIIA Non-Small Cell Lung Cancer (according to version 9th of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and previously untreated.
- Tumor should be considered resectable before study entry by a multidisciplinary team.
- ECOG Performance Status of 0 or 1
- At least 1 unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
- Able to comply with study and follow-up procedures
- Major organ function For regular test results(no blood transfusion within 14 days):
- Hemoglobin(HB)≥90g/L;
- Absolute neutrophils count(ANC)≥1.5×109/L;
- Blood platelets(PLT)≥100×109/L
Biochemical tests results defined as follows:
- Total bilirubin(TBIL)≤1.5 times the upper limit of normal (ULN) ;
- Alanine aminotransferase (ALT) and aspartate aminotransgerase AST≤2.5*ULN,
- Creatinine(Cr)≤1.5*ULN or Creatinine Clearance rate (CCr)≥60 ml/min; Coagulation test: INR/APTT within normal limits Doppler ultrasound assessment:left ventricular ejection fraction (LVEF) ≥the lower limit of normal value (50%).
- The patients need to have a forced expiratory volume (FEV1) ≥ 1.2 liters
- Subjects must provide fresh tissues or formalin-fixed tumor tissue samples at or the diagnosis NSCLC for mIF.
Exclusion Criteria:
- 1) All patients carrying activating mutations in the TK domain of EGFR or any variety of alterations in the ALK gene.
- Small cell lung cancer (including patients with mixed small cell lung cancer and non-small cell lung cancer).
- Any anti-tumor treatment within the past 5 years, including chemotherapy, radiotherapy, target therapy or other immunotherapy 4) Severe acute or chronic infections, including: hepatits B, hepatits C, HIV etc 5) Patients with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included.
- Histologically confirmed adenosquamous carcinoma 7) Any prior treatment of antibody/drug that targets at T-cell coregulatory proteins 8) Subjects have interstitial lung disease (ILD), or a history of ILD that required corticosteroid treatment.
- Women in pregnancy or lactation. 10) Patients who are allergic to any of the agent or any ingredient
Quoted from ClinicalTrials.gov, NCT06987734, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06987734, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.